−$13.77 (32.85%) At close $28.15 · Tue
☾After Hours +$0.11 (0.40%) Nov 3, 7:59 PM ET
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
AllSci and others reported Supernus and Indivior completed their merger on November 2, 2026 · not confirmed by the company
Sources: AllSci · BioPharmaWatch
AI generated · Not investment advice
AllSci and others reported Supernus and Indivior completed their merger on November 2, 2026 · not confirmed by the company
Reported: a named outlet’s report, not confirmed by the company.
Sources: AllSci · BioPharmaWatch
Written Nov 3, 1:30 PM ET · last check Nov 3, 7:30 PM ET
AI generated · May contain errors · Not investment adviceSummarized from public reports · Sources linkedSign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about SUPN?
The Motley Fool
Why Indivior Pharmaceuticals Stock Topped the Market TodayIndivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, creating a leading CNS biopharmaceutical company. The combined entity will operate under the Supernus name and ticker, with Indivior shareholders receiving a $1 billion special cash dividend and owning approximately 56.5% of the merged company. The merger aims to achieve $125 million in annual cost synergies.
Zacks Investment Research
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesSupernus Pharmaceuticals beat Q3 2026 earnings expectations with $0.93 EPS versus consensus of $0.49, representing an 89.80% surprise. Revenue of $226.77 million also exceeded estimates by 1.39%. However, the stock has underperformed the market by 17.3% year-to-date and carries a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release.
GlobeNewswire Inc.
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)Supernus Pharmaceuticals announced that the FDA has granted seven years of orphan-drug market exclusivity for ONAPGO (apomorphine HCl), a subcutaneous infusion device for treating motor fluctuations in advanced Parkinson's disease patients. The exclusivity period began February 3, 2025. Additionally, the company submitted a supplemental New Drug Application for a second supplier with expected FDA approval by mid-2027.
Headlines open the publisher's site.
No threads yet
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›
